Ligand Pharmaceuticals (LGND) Work In Process (2023 - 2024)
Ligand Pharmaceuticals (LGND) reported Work In Process of $3.9 million for Q4 2024, up 1911.79% on a YoY basis from $195000.0 in Q1 2024, and up 1408.85% sequentially from $260000.0 in Q3 2024.
Ligand Pharmaceuticals (LGND) Work In Process (2023 - 2024) Analysis & Trends
Ligand Pharmaceuticals (LGND) has 2 years of Work In Process data on file, last reported at $3.9 million in Q4 2024.
- For the quarter ending Q4 2024, Work In Process rose 1911.79% year-over-year to $3.9 million; the trailing twelve-month figure through Dec 2024 stood at $3.9 million (up 1911.79% YoY), and the FY2024 full-year result was $3.9 million, up 1911.79% from the prior year.
- Work In Process climbed to $3.9 million in Q4 2024, from $260000.0 in the prior quarter.
- In the past five years, Work In Process ranged from a high of $3.9 million in Q4 2024 to a low of $195000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Ligand Pharmaceuticals | 6.05 Bn | 5.27 Bn | 48.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 3.92 Mn |
| Sep 30, 2024 | 260,000.00 |
| Jun 30, 2024 | 548,000.00 |
| Dec 31, 2023 | 195,000.00 |